NCT03536728: Oral AMXT 1501 Dicaprate in Combination With DFMO

NCT03536728
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Misc Inhibitor, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03536728

Comments are closed.

Up ↑